...
search icon
indv-img

Indivior PLC Ordinary Shares, Common Stock

INDV

NSQ

$9.83

-$0.25

(-2.48%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$1.24B
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
338.99K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.27
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$7.33 L
$23.22 H
$9.83

About Indivior PLC Ordinary Shares, Common Stock

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameINDVSectorS&P500
1-Week Return2.61%-0.03%1.53%
1-Month Return-12.31%4.56%4.75%
3-Month Return-3.15%1.29%2.77%
6-Month Return-19.29%-3.54%12.18%
1-Year Return-44.93%1.59%22.34%
3-Year Return228.76%13.55%38.91%
5-Year Return1761.74%40.85%80.7%
10-Year Return306.2%105.52%190.95%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue785.00M689.68M777.48M884.63M1.09B[{"date":"2019-12-31","value":71.82,"profit":true},{"date":"2020-12-31","value":63.1,"profit":true},{"date":"2021-12-31","value":71.13,"profit":true},{"date":"2022-12-31","value":80.94,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Cost of Revenue140.00M116.19M137.61M168.87M186.00M[{"date":"2019-12-31","value":75.27,"profit":true},{"date":"2020-12-31","value":62.47,"profit":true},{"date":"2021-12-31","value":73.98,"profit":true},{"date":"2022-12-31","value":90.79,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Profit645.00M573.49M639.87M715.75M907.00M[{"date":"2019-12-31","value":71.11,"profit":true},{"date":"2020-12-31","value":63.23,"profit":true},{"date":"2021-12-31","value":70.55,"profit":true},{"date":"2022-12-31","value":78.91,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Margin82.17%83.15%82.30%80.91%82.98%[{"date":"2019-12-31","value":98.81,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":98.98,"profit":true},{"date":"2022-12-31","value":97.3,"profit":true},{"date":"2023-12-31","value":99.8,"profit":true}]
Operating Expenses607.00M479.69M456.07M510.55M911.00M[{"date":"2019-12-31","value":66.63,"profit":true},{"date":"2020-12-31","value":52.65,"profit":true},{"date":"2021-12-31","value":50.06,"profit":true},{"date":"2022-12-31","value":56.04,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Income178.00M93.81M183.80M205.20M(4.00M)[{"date":"2019-12-31","value":86.74,"profit":true},{"date":"2020-12-31","value":45.71,"profit":true},{"date":"2021-12-31","value":89.57,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-1.95,"profit":false}]
Total Non-Operating Income/Expense-(34.00M)(46.00M)(20.00M)10.00M[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-340,"profit":false},{"date":"2021-12-31","value":-460,"profit":false},{"date":"2022-12-31","value":-200,"profit":false},{"date":"2023-12-31","value":100,"profit":true}]
Pre-Tax Income180.00M(184.41M)186.75M(93.27M)1.00M[{"date":"2019-12-31","value":96.38,"profit":true},{"date":"2020-12-31","value":-98.75,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-49.95,"profit":false},{"date":"2023-12-31","value":0.54,"profit":true}]
Income Taxes46.00M(26.65M)(14.74M)(41.24M)(1.00M)[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-57.93,"profit":false},{"date":"2021-12-31","value":-32.05,"profit":false},{"date":"2022-12-31","value":-89.65,"profit":false},{"date":"2023-12-31","value":-2.17,"profit":false}]
Income After Taxes134.00M(157.76M)201.50M(52.04M)2.00M[{"date":"2019-12-31","value":66.5,"profit":true},{"date":"2020-12-31","value":-78.3,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-25.83,"profit":false},{"date":"2023-12-31","value":0.99,"profit":true}]
Income From Continuous Operations134.00M(148.00M)205.00M(53.00M)2.00M[{"date":"2019-12-31","value":65.37,"profit":true},{"date":"2020-12-31","value":-72.2,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-25.85,"profit":false},{"date":"2023-12-31","value":0.98,"profit":true}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income134.00M(157.76M)205.00M(52.04M)2.00M[{"date":"2019-12-31","value":65.37,"profit":true},{"date":"2020-12-31","value":-76.96,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-25.38,"profit":false},{"date":"2023-12-31","value":0.98,"profit":true}]
EPS (Diluted)0.86(1.05)1.31(0.44)0.24[{"date":"2019-12-31","value":65.59,"profit":true},{"date":"2020-12-31","value":-80.24,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-33.71,"profit":false},{"date":"2023-12-31","value":18.31,"profit":true}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

INDV
Cash Ratio 0.33
Current Ratio 0.83
Quick Ratio 0.65

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

INDV
ROA (LTM) 11.27%
ROE (LTM) 12.20%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

INDV
Debt Ratio Lower is generally better. Negative is bad. 1.11
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. -0.11

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

INDV
Trailing PE NM
Forward PE NM
P/S (TTM) 1.04
P/B 145.25
Price/FCF NM
EV/R 1.01
EV/Ebitda 21.00

FAQs

What is Indivior PLC Ordinary Shares share price today?

Indivior PLC Ordinary Shares (INDV) share price today is $9.83

Can Indians buy Indivior PLC Ordinary Shares shares?

Yes, Indians can buy shares of Indivior PLC Ordinary Shares (INDV) on Vested. To buy Indivior PLC Ordinary Shares from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in INDV stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Indivior PLC Ordinary Shares be purchased?

Yes, you can purchase fractional shares of Indivior PLC Ordinary Shares (INDV) via the Vested app. You can start investing in Indivior PLC Ordinary Shares (INDV) with a minimum investment of $1.

How to invest in Indivior PLC Ordinary Shares shares from India?

You can invest in shares of Indivior PLC Ordinary Shares (INDV) via Vested in three simple steps:

  • Click on Sign Up or Invest in INDV stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Indivior PLC Ordinary Shares shares
What is Indivior PLC Ordinary Shares 52-week high and low stock price?

The 52-week high price of Indivior PLC Ordinary Shares (INDV) is $23.22. The 52-week low price of Indivior PLC Ordinary Shares (INDV) is $7.33.

What is Indivior PLC Ordinary Shares price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Indivior PLC Ordinary Shares (INDV) is 145.25

What is the Market Cap of Indivior PLC Ordinary Shares?

The market capitalization of Indivior PLC Ordinary Shares (INDV) is $1.24B

What is Indivior PLC Ordinary Shares’s stock symbol?

The stock symbol (or ticker) of Indivior PLC Ordinary Shares is INDV

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top